ASCO 2019: New standard first-line therapy for EGFR mutant NSCLC

Bjørn Henning Grønberg | ASCO 2019 | Juni 6, 2019

Föreläsare: Bjørn Henning Grønberg

Standard first-line therapy for EGFR mutant advanced non-small cell lung cancer (NSCLC) is an EGFR-directed oral TKI. Adding pemetrexed-carboplatin chemotherapy to gefitinib significantly prolonged progression free and overall survival but also increased toxicity. The data from this study support, that pemetrexed-carboplatin-gefitinib represents a new standard first-line therapy for EGFR mutant NSCLC.